###### Strengths and limitations of this study

-   This meta-analysis is the first systematic review and meta-analysis evaluating ginkgo biloba extract as an acute mountain sickness prophylactic.

-   This meta-analysis was strengthened by a thorough quality assessment of each enrolled study and comprehensive subgroup analyses.

-   There is notable heterogeneity and the small number of studies limits the analyses, but heterogeneity decreased after excluding studies with high risk of bias.

-   Insufficient power may be an issue in this meta-analysis.

-   Further large randomised controlled studies are warranted.

Introduction {#s1}
============

Background {#s1a}
----------

Rapid ascent from low to high altitude (\>2500 m above sea level) is often followed by headache, fatigue, shortness of breath, sleeplessness and anorexia, a symptom complex called acute mountain sickness (AMS).[@R1] The Lake Louise Score (LLS) questionnaire[@R2] and the Environmental Symptom Questionnaire III[@R3] are two tools to diagnose and evaluate the severity of AMS. AMS is more likely to happen at altitudes higher than 2500 m,[@R4] and worldwide studies reported an incidence of AMS of 25%--37% at 1900--3400 m.[@R1] Children are more prone to develop AMS, with an incidence of 59%.[@R6]

The pathophysiology of AMS is associated with cerebral oedema, with the most compelling evidence coming from the brain MRI study of Hackett *et al*,[@R7] which showed intense T2 signals in the white matter, particularly in the splenium and corpus callosum. Vasogenic leakage increases the permeability of the endothelium, causing an elevation in intravascular pressures and inducing hypoxaemia. In addition, hypoxic ventilatory response and activation of the renin--angiotensin--aldosterone system are also reported to be associated with AMS.[@R8] The most effective method to prevent AMS is gradual ascent. The most common pharmacological agent used to prevent AMS is acetazolamide.[@R9] However, acetazolamide can cause paresthesia, dysgeusia, and sometimes nausea or drowsiness.[@R10] Its use is also contraindicated in patients with a history of anaphylaxis to sulfa antibiotics or acetazolamide.

Importance {#s1b}
----------

Ginkgo biloba extract (GBE) is an option for those seeking a natural alternative treatment. GBE is found to decrease tissue hypoxia, induce vasodilation, and reduce free-radical production and lung leak, which may in turn prevent AMS.[@R11] Roncin *et al* [@R15] in 1996 published the first study to suggest that GBE can prevent AMS. However, not all subsequent studies have shown benefit.[@R13] To date, there is no best evidence to support the effectiveness of GBE.

Goal of this investigation {#s1c}
--------------------------

The aim of our study was to assess the effectiveness of GBE as prophylaxis for AMS by conducting a meta-analysis and systematic review of the relevant literature.

Methods {#s2}
=======

Databases and search strategy {#s2a}
-----------------------------

We searched the Cochrane Library, EMBASE, Google Scholar and PubMed databases for articles published up to 20 May 2017. No limits were applied to our Boolean search strategy, which included keywords ('Ginkgo', 'Altitude Sickness', 'Mountain'), medical subject headings ('Ginkgo biloba', 'Altitude Sickness') and Emtree terms ('Ginkgo biloba', 'altitude disease'). The full search strategy for database is provided in the online [supplementary file](#SP1){ref-type="supplementary-material"}. References from retrieved articles were also examined to identify other relevant articles.
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Studies were included in the systematic review if they (1) were randomised controlled trials (RCTs) of healthy non-acclimatised adult between the ages of 18 and 60 years; (2) compared GBE with placebo; (3) were conducted in humans; and (4) were studies that diagnosed AMS using the Lake Louise Score or the Environmental Symptom Questionnaire Acute Mountain Sickness-Cerebral score (AMS-C). We excluded studies with subjects who were pregnant and had symptoms consistent with AMS at baseline. Studies were also excluded if they were irrelevant to the aim of the study, were animal studies, lacked a placebo group, or were published as review articles, case reports, editorials or letters. The systematic review and meta-analysis was conducted under the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (see online online [supplementary checklist](#SP2){ref-type="supplementary-material"}).
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Outcome measures {#s2b}
----------------

AMS was defined as an AMS-C score ≥0.7 or an LLS ≥3 with headache. The primary outcome was the relative risk (RR) of AMS in participants receiving GBE for prophylaxis. We only extracted data when they were available in dichotomous form. The secondary outcomes of the included studies are summarised in online [supplementary table 1](#SP1){ref-type="supplementary-material"}.

Data extraction and assessment of methodological quality {#s2c}
--------------------------------------------------------

Two reviewers (T-YT and Y-CS) independently screened the titles and abstracts of all articles identified from the search strategy. Inter-reviewer disagreements concerning the inclusion or exclusion of a study were resolved by consensus and, if necessary, consultation with a third reviewer (S-HW).

The Cochrane Collaboration's tool was used to assess the risk of selection, performance, detection, attrition and reporting biases in the included randomised trials.[@R21] We defined studies as 'high risk of bias' if one or more key domains is taken as high risk in the checklist. All coauthors discussed and made the final decisions about the overall risk of bias in the included trials. If data were not readily available or clear, we contacted the first authors and the corresponding authors to get further information. If studies were found to be at high risk of bias, meta-analyses stratified by study quality were performed.

Both reviewers independently extracted data from the articles selected for inclusion. The extracted data included the name of the first author, year of publication, numbers of participants, gender, starting and final altitudes, AMS scoring definitions, prescriptions of GBE, days of treatment prior to ascent, and number of individuals with AMS in the treatment and control groups.

Data collection, data processing and primary data analysis {#s2d}
----------------------------------------------------------

Pooled RRs with corresponding 95% CIs are derived for all studies and different subgroups of interest. The main outcome measure was the RR of AMS in participants receiving GBE for prophylaxis. Random-effect models with DerSimonian and Laird method were selected for these analyses. The pooled risk difference (RD) was also measured as the alternative outcome. The pooled RD is the difference between the observed risks (proportions of participants with AMS) in the two groups.

We conducted subgroup analyses based on the quality of studies, starting altitude, number of treatment days before ascending and dosage of GBE.[@R22] Between-study heterogeneity was evaluated with the I^2^ statistic.[@R25] The Egger regression asymmetry test and Begg adjusted rank correlation test were applied for assessment of potential publication bias.[@R26] We also conducted sensitivity analysis to evaluate the influence of each study on the overall pooled estimate. In dealing with zero cells, we add 0.5 to all cells of the 2×2 table for the study. Analyses were all conducted using STATA V.11.0. All statistical tests were two-sided and were considered significant when the p value was 0.05 or less.

Patient and public involvement statement {#s2e}
----------------------------------------

Participants and the public sector were not directly involved in the design and conduct of this study.

Results {#s3}
=======

The literature search and study selection process are summarised in [figure 1](#F1){ref-type="fig"}. After the exclusion of duplicate studies, non-relevant studies and other studies that met the exclusion criteria based on a screening of article titles and abstracts, 38 potentially relevant studies were retrieved for full review.

![Trial selection algorithm. AMS, acute mountain sickness.](bmjopen-2018-022005f01){#F1}

One publication was retrieved by hand search of references. In this study, Wang *et al* [@R28] compared the prophylactic effect of GBE with that of other Chinese medications on AMS. However, the study had no placebo group design[@R29] and had to be excluded from our meta-analysis.

In the randomised, double-blind study by Ke *et al* in 2013,[@R20] AMS was reported as a secondary outcome and the number of events in each group was not reported. We contacted the first and corresponding authors by email but (as of 12 June 2018) received no response. Since the published data could not be included for analysis, we excluded this study.

Six published articles met all eligibility criteria after a careful review process.[@R13] In the article published by Leadbetter *et al*,[@R19] two RCTs were conducted. As a result, a total of 7 study groups with 451 participants were enrolled. The characteristics of these studies and the participants are listed in [table 1](#T1){ref-type="table"}. Four study groups[@R13] demonstrated the efficacy of GBE in preventing AMS, while three[@R17] did not. All studies had small numbers of subjects except the one by Gertsch and colleagues.[@R17] Of note, participants in the study conducted by Gertsch *et al* [@R17] published in 2004 started GBE treatment at high altitude (4280--4358 m), which was different from the other studies. Further information such as study dosage, prescription frequency, number of days prior to ascending and source of GBE is summarised in [table 2](#T2){ref-type="table"}. The number of AMS events and its incidence is summarised in [figure 2](#F2){ref-type="fig"}. The quality of evidence of these studies as assessed by Cochrane Collaboration's tool is presented in [table 3](#T3){ref-type="table"}. Two of six articles were not double-blinded and both of them included male participants only.[@R13] The study conducted by Gertsch *et al* [@R16] in 2002 used 'first-come first-served basis' after receiving signed consent. Therefore, we judge it as 'unclear random-sequence generation'. In addition, we appraised it as incomplete outcome data (attrition bias) because the study presented data on only 26 subjects when the intention was to enrol 100 subjects.
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###### 

Characteristics of included studies

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                 Participants (n)   Male (%)   Starting altitude (m)   Altitude reached (m)   Ascent rate (m/hour)   AMS definition
  ------------------------------ ------------------ ---------- ----------------------- ---------------------- ---------------------- -------------------------------
  Roncin *et al*,[@R15] 1996     44                 100        1800                    5400                   15                     AMS-C\>0.7

  Gertsch *et al*, [@R16] 2002   26                 46         0                       4205                   1402                   LLS≥3 with HA

  Gertsch *et al*, [@R17] 2004   243                70         4280--4358              4928                   10--20                 LLS≥3 with HA

  Chow *et al*,[@R18] 2005       37                 54         1230                    3800                   1285                   LLS≥3 with HA

  Moraga *et al*,[@R13] 2007     24                 100        0                       3696                   435                    LLS≥3 or one symptom score ≥3

  Leadbetter *et al*,[@R19]\     40                 45         2000                    4300                   1150                   AMS-C≥0.7 + LLS≥3 with HA
  2009 study 1                                                                                                                       

  Leadbetter *et al*,[@R19]\     37                 44         2000                    4300                   1150                   AMS-C≥0.7 + LLS≥3 with HA
  2009 study 2                                                                                                                       
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------

AMS, acute mountain sickness; AMS-C, the Environmental Symptom Questionnaire III Acute Mountain Sickness-Cerebral score; HA, headache; LLS, Lake Louise Score.

###### 

Characteristics of included studies, sources, dosage and duration of ginkgo biloba

  ------------------------------------------------------------------------------------------------------------------------------------------
                                Ginkgo biloba extract source                   Dose                      Days of treatment prior to ascent
  ----------------------------- ---------------------------------------------- ------------------------- -----------------------------------
  Roncin *et al*,[@R15] 1996    Tanakan DCI: EGb 761, Ipsen, Paris, France     60 mg twice daily         0

  Gertsch *et al*,[@R16] 2002   GK501 Memfit, EGb 761, Pharmaton               60 mg three times a day   1

  Gertsch *et al*,[@R17] 2004   GK501 International, Pharmaton                 120 mg twice daily        1--2

  Chow *et al*,[@R18] 2005      Ginkgo biloba 120 mg, Vegetarian NOW Foods     120 mg twice daily        5

  Moraga *et al*,[@R13] 2007    EGb 761 Rokan, Andromaco Laboratories, Chile   80 mg twice daily         1

  Leadbetter *et al*,[@R19]\    Spectrum Quality, Laboratories Products        120 mg twice daily        4
  2009, study 1                                                                                          

  Leadbetter *et al*,[@R19]\    Technical Sourcing                             120 mg twice daily        3
  2009, study 2                                                                                          
  ------------------------------------------------------------------------------------------------------------------------------------------

###### 

Risk of bias in included studies

  Risk of bias domain                               Roncin *et al*,[@R15] 1996   Gertsch *et al*,[@R16] 2002   Gertsch *et al*,[@R17] 2004   Chow *et al*,[@R18] 2005   Moraga *et al*,[@R13] 2007   Leadbetter *et al*,[@R19] 2009
  ------------------------------------------------- ---------------------------- ----------------------------- ----------------------------- -------------------------- ---------------------------- --------------------------------
  Random-sequence generation (selection bias)       Unclear                      Unclear                       Low                           Low                        Low                          Low
  Allocation concealment (selection bias)           Unclear                      Low                           Low                           Low                        Unclear                      Low
  Blinding of participants (performance bias)       High                         Low                           Low                           Low                        High                         Low
  Blinding of outcome assessment (detection bias)   High                         Low                           Low                           Low                        High                         Low
  Incomplete outcome data (attrition bias)          High                         High                          Low                           Low                        Low                          Low
  Selective outcome reporting (reporting bias)      Low                          Low                           Low                           Low                        Low                          Low
  Other source of bias                              High                         Low                           High                          Low                        High                         Low
  Overall risk of bias                              High                         High                          Low                           Low                        High                         Low

In the primary meta-analysis of all seven study groups, GBE showed trend of AMS prophylaxis, but it is not statistically significant (RR=0.68; 95% CI 0.45 to 1.04; p=0.08) ([figure 2](#F2){ref-type="fig"}). The I^2^ statistic was 58.7% (p=0.02), indicating substantial heterogeneity. The pooled RD revealed a significant risk reduction in participants who use GBE (RD=−25%; 95% CI, from a reduction of 45% to 6%; p\<0.001) ([figure 3](#F3){ref-type="fig"}). After excluding three high-risk bias studies,[@R13] the I^2^ statistic became 40.2% (p=0.17) and the result did not change (RR=0.84; 95% CI 0.59 to 1.21; p=0.36). In the same subgroup the pooled RD is also not statistically significant (RD=−9.7%; 95% CI, from a reduction of 27.4% to 7.9%; p=0.28). The Egger's test and Begg's test (p=0.22 and p=0.31, respectively) indicate the absence of statistical evidence of publication bias after excluding our presumed high-risk bias articles.

![Pooled risk difference of enrolled studies. GBE, ginkgo biloba extract; RD, risk difference.](bmjopen-2018-022005f03){#F3}

Sensitivity analysis was conducted by removing one trial at a time to determine what influence each study had on the pooled analysis. The pooled result seemed to be robust. For example, removing the study conducted by Leadbetter *et al* in 2009[@R19] only changed the pooled estimate from 0.68 to 0.74 (95% CI 0.48 to 1.16; p=0.19; see online [supplementary figure 1](#SP3){ref-type="supplementary-material"}).
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The results of several preplanned subgroup analyses were similar. Excluding the study by Gertsch and colleagues in 2004,[@R17] GBE was not prophylactic when the starting altitude was below 2500 m (RR=0.56; 95% CI 0.31 to 1.01).[@R13] Regarding the number of treatment days before ascending, GBE was not prophylactic when given '3--5 days prior to ascent'[@R18] (RR=0.72; 95% CI 0.41 to 1.26) or '0--2 days prior to ascent'[@R13] (RR=0.56; 95% CI 0.25 to 1.25). Dosage of GBE was also not prophylactic for AMS when given 'less than 200 mg per day'[@R13] (RR=0.16; 95% CI 0.01 to 2.57) or 'more than 200 mg per day'[@R17] (RR=0.84; 95% CI 0.59 to 1.21). Data on the number of participants and enrolled studies in each subgroup are summarised in online [supplementary table 2](#SP1){ref-type="supplementary-material"}.

Discussion {#s4}
==========

To our knowledge, this is the first meta-analysis of RCTs evaluating GBE as an AMS prophylactic. In pooled analyses, we found that although GBE may tend towards AMS prophylaxis, it had no statistically significant prophylactic effect (RR=0.68; 95% CI 0.45 to 1.04; p=0.08). The results of several subgroup analyses were similar. GBE also failed to show benefits in preventing AMS in low-risk bias studies, studies in which the starting altitude was low, studies differing in the initial treatment regimen prior to ascent and different dosage of GBE.

The effectiveness of GBE in AMS prophylaxis has been reported.[@R13] Zhang and colleagues[@R29] in 2003 reported that GBE was the most effective of six Chinese medicines tested for AMS prophylaxis. GBE has been used primarily for the treatment of dementias (eg, Alzheimer's disease), peripheral vascular diseases (eg, intermittent claudication) and neurosensory problems (eg, tinnitus).[@R30] Hypotheses have been proposed to explain the possible role that GBE plays in preventing AMS. Hypoxia is a common feature of AMS. Several studies have suggested that nitric oxide (NO) may play a pathogenic role in AMS by mediating hypoxia-induced cerebral vasodilation in humans.[@R11] GBE was found to be an NO scavenger. NO scavenging can result in decreased intracellular NO level.[@R14] Furthermore, GBE may inhibit phosphodiesterase activity, thus enhancing relaxation of parietal smooth muscle cells and so lead to vasodilation of parietal vessels. Vasodilation in turn increases tissue perfusion and decreases local hypoxia.[@R14] Other potential mechanisms include increasing endogenous antioxidants,[@R31] reducing free-radical production[@R32] and reducing lung leak during hypoxia.[@R33] GBE was also shown to prevent high-altitude pulmonary oedema in a rat model.[@R34]

On the other hand, several studies failed to demonstrate the benefit of GBE in AMS prophylaxis.[@R17] The duration of therapy before ascent, dosage of GBE and differences in the altitude at which GBE is initiated may account for the conflicts between trial results. To test these hypotheses, we conducted subgroup analyses and obtained similar results to those obtained with the original pooled data. Another explanation for the differences in efficacy may be variation in the GBE composition. For instance, Leadbetter and colleagues[@R19] in 2009 compared GBE from two different sources and found they differed in composition as well as ability to reduce the incidence and severity of AMS following rapid ascent to high altitude. The German Federal Institute for Drugs and Medicinal Devices Commission E recommends similar specifications for standardisation of GBE. All included studies used GBE that met the German E commission standard, but most of the studies use products from different companies. As an herbal supplement, more than 60% of GBE component is not mandated by law and composition may vary considerably between manufacturers. A lack of bioequivalence has been noted between brands of GBE.[@R35]

Limitations {#s4a}
-----------

Our systematic review has several limitations. First, to limit the influence of study biases on pooled evaluation, we decided to only include RCTs. However, there were few RCTs in this field. Moreover, only four of six RCTs were double-blinded. Second, because of the difficulty in carrying out high-altitude medicine studies, many studies involved only a small number of cases. In our primary pooled analysis, a total of 451 participants were enrolled. Insufficient power may be an issue in this meta-analysis. There are not enough data to show the statistically significant effect of GBE on preventing AMS, and further studies are warranted. Third, the participants were predominantly adult men, and whether there is gender or age difference between treatment (GBE vs placebo) groups or response (no AMS vs AMS) groups is unknown. Fourth, GBE is a complex mixture of natural components. It is difficult to standardise all components. A lack of consistency between commercially available GBE preparations may explain these differing results. Finally, differences between studies in factors such as the strength, rate of ascent and other characteristics of participants may also account for inconsistent results.

Conclusion {#s5}
==========

The currently available data suggest that although GBE may tend towards AMS prophylaxis, there are not enough data to show the statistically significant effect of GBE on preventing AMS. Further large randomised control studies are warranted.
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